We are live on
!
Find out more
HCM
Horan Capital Management Portfolio holdings
AUM
$794M
1-Year Est. Return
30.86%
This Fund
S&P 500
This Quarter
Est. Return
+3.08%
1 Year Est. Return
+30.86%
3 Year Est. Return
+69.18%
5 Year Est. Return
+124.11%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$18.2M
(+4.2%)
Cap. Flow
+$5.66M
Cap. Flow
% of AUM
1.24%
Top 10 Holdings %
Top 10 Hldgs %
45.82%
Holding
86
New
5
Increased
17
Reduced
46
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.74M |
| 2 |
CVS Health
CVS
|
+$6.5M |
| 3 |
Biogen
BIIB
|
+$3.72M |
| 4 |
Schwab US Aggregate Bond ETF
SCHZ
|
+$2.66M |
| 5 |
Gilead Sciences
GILD
|
+$1.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tapestry
TPR
|
+$7.81M |
| 2 |
Fossil Group
FOSL
|
+$4.28M |
| 3 |
Merck
MRK
|
+$2.87M |
| 4 |
US Bancorp
USB
|
+$789K |
| 5 |
T. Rowe Price
TROW
|
+$767K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.17% |
| 2 | Healthcare | 16.72% |
| 3 | Technology | 14.9% |
| 4 | Industrials | 10.1% |
| 5 | Consumer Staples | 9.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Medtronic
MDT
$112B
| – | – |
-1,912
| Closed | -$154K |
|
77
3M
MMM
$91.8B
| – | – |
-682
| Closed | -$109K |
|
|
78
Merck
MRK
$322B
| – | – |
-47,335
| Closed | -$2.87M |
|
79
Netflix
NFLX
$307B
| – | – |
-17,720
| Closed | -$261K |
|
80
Northrop Grumman
NOC
$76B
| – | – |
-485
| Closed | -$115K |
|
|
81
Tapestry
TPR
$30.3B
| – | – |
-188,953
| Closed | -$7.81M |
|
|
82
T. Rowe Price
TROW
$25.5B
| – | – |
-11,256
| Closed | -$767K |
|
83
Vanguard Morningstar Mid-Cap ETF
VO
$106B
| – | – |
-4,756
| Closed | -$165K |
|
|
HA
84
DELISTED
Hawaiian Holdings, Inc.
HA
| – | – |
-5,014
| Closed | -$232K |
|
|
AET
85
DELISTED
Aetna Inc
AET
| – | – |
-1,237
| Closed | -$157K |
|
Similar funds
DBC
BII
HCMNY
DK
AVAX
IVA
LCM
WEC
Horan Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Horan Capital Management held 86 positions worth $457M, up 4.2% from $439M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Horan Capital Management's Q2 2017 filing shows 5 new, 17 increased, 46 reduced and 18 closed positions. Its largest new stake was Schwab US Aggregate Bond ETF: 101,830 shares worth $2.66M. The largest sale was Tapestry, an estimated $7.81M.
By sector, the portfolio is most concentrated in Financials at 25% of assets, down from 25% a quarter earlier, followed by Healthcare and Technology.
- Horan Capital Management's largest Q2 2017 buy was Schwab US Aggregate Bond ETF: 101,830 shares worth $2.66M.
- Horan Capital Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $7.74M increase.
- Horan Capital Management's biggest Q2 2017 reduction was US Bancorp, cutting an estimated $789K.
- Horan Capital Management fully exited Tapestry in Q2 2017, selling an estimated $7.81M.
- Horan Capital Management's ten largest holdings make up 46% of its $457M portfolio in Q2 2017.
- Horan Capital Management opened 5 new positions and closed 18 in Q2 2017.
- Horan Capital Management's portfolio value rose 4.2% quarter-over-quarter to $457M.
Based on Horan Capital Management's 13F filing for Q2 2017, filed 17 Jul 2017.